/

Nebivolol 5mg 30 tablets

$23.00

Essential hypertension. Chronic heart failure of mild or moderate severity as an adjunct to standard treatments for patients over 70 years of age.

Free shipping. Delivery time is 3-6 weeks. Please, consider it before ordering.

Description

Nebivolol Composition:
active substance: nebivolol; 1 tablet contains nebivolol hydrochloride 5.45 mg, which corresponds to 5 mg of nebivolol;
Excipients: lactose monohydrate, macrogol 6000, croscarmellose sodium, magnesium stearate, colloidal anhydrous silica.

Indications

Essential hypertension.

Treatment of stable chronic heart failure light and moderate in addition to standard therapy in patients aged 70 years.

 

Contraindications

Hypersensitivity to the active substance or any other drug. Liver failure or liver dysfunction. Acute heart failure, cardiogenic shock or episodes of heart failure decompensation requiring intravenous drugs with positive inotropic effect. Sick sinus syndrome, including sinoatrial block, atrioventricular (AV) -blokada II-III (without artificial pacemaker). Bronchospasm and bronchial asthma in history. Untreated pheochromocytoma. Metabolic acidosis. Bradycardia (before treatment heart rate less than 60 beats per minute.). Hypotension (systolic blood pressure less than 90 mmHg. In.), Severe peripheral circulation.

Dosage & Administration

Essential hypertension. Adult patients take 1 pill of nebivolol (5 mg) per day, possibly at the same time. The drug can be taken with food. Anti-hypertensive effect becomes evident after 1-2 weeks of treatment, but sometimes the optimal effect is observed only after 4 weeks.

Nebitens can be used both alone and in combination with other antihypertensive agents. Until additional antihypertensive effect was observed only in combination with its 12,5-25 mg hydrochlorothiazide.

Chronic heart failure. Treatment of chronic heart failure should begin with a slow dose titration to achieve optimal individual maintenance dose. Such patients prescribed the drug if there is chronic heart failure without acute episodes of decompensation within the last 6 weeks.